JUBLPHARMA · Jubilant Pharmova Limited · BSE · Filed 7 Oct · 1 min read

Jubilant Pharmova Board to Meet 12 October on NCD Fundraising

The board will consider raising funds via non-convertible debentures or other permitted securities, and seeking shareholder approval if required.

What was filed

Jubilant Pharmova Limited has given prior intimation, under Regulation 29 of SEBI's LODR Regulations, that its Board of Directors will meet on Monday, 12 October 2026. Per the filing, the board will consider and approve raising funds through the issuance of Non-Convertible Debentures (NCDs) and/or such other securities as may be permitted under applicable laws, and will also consider seeking shareholders' approval as may be required.

What the filing does not say

This is a scheduling notice, not a decision. The filing discloses no amount, no coupon, no tenor, and no specific instrument beyond the general reference to NCDs or other permitted securities. Whether funds are raised at all, and on what terms, would only be known after the board meets and makes a further disclosure.

For a holder, this flags that the company may add debt or other securities to its capital structure and may put a related proposal to shareholders; the terms and scale remain undisclosed until the board meets and discloses its decision.